Company Profile

Acera Biosciences Inc
Profile last edited on: 1/11/19      CAGE: 4X3M5      UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1479 Gortner Avenue Suite 240
St Paul, MN 55108
   (612) 624-3071
Location: Single
Congr. District: 04
County: Ramsey

Public Profile

Some time after c. 2007, the firm appears to have been closed down. Acera Biosciences, Inc. provides biotech solutions for the development of drug production systems for abandoned or under-explored natural compounds. The company also provides the modification of compounds through the attachment of unique sugars. Acera's two current products include the Acera Drug Production Development Solution and the Acera Drug Modification Solution.. Acera Biosciences, Inc (Acera) is a biotechnology company providing natural product biosynthetic pathways and expression systems for the development and manufacturing of: natural products, new chemical entities (NCEs), modification of new or existing drug leads, and development of biocatalysts. The targeted industries for products and services include pharmaceutical, biotechnology, and agrochemical. Acera combines proprietary and industrial technologies for cloning, expressing, and manipulating genetic material to provide high value chemicals and biocatalysts. Acera has an exclusive licensing agreement with the University of Minnesota for certain patented technologies,as well as future technology refinements, improvements, and inventions. Thus, Acera has the technology and commercial resources to play a key role in drug development from discovery through manufacturing along with earning worldwide recognition as a preferred supplier of fine chemicals and biocatalysts. Acera utilizes proprietary technology to isolate, clone, define, and express biosynthetic pathways in the manufacturing of unique natural product compounds foruse as new or the modification of existing drugs. Acera can provide these services in support of drug research and development of third party partners.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2003 1 NIH $144,013
Project Title: Heterologous Expression of Marine Natural Products
2002 1 NIH $148,400
Project Title: Combinatorial Biosynthesis of Novel Bioreductive Agents
2001 1 NIH $100,000
Project Title: Improving Glycosyltransferase by RACHITT Gene Shuffling
2000 1 NIH $166,303
Project Title: Engineered Biosynthesis of Novel Ketolide Antibiotics
2000 1 NIH $98,580
Project Title: Glycosylation of Polyketides by a Glycosyltransferase

Key People / Management

  William Amba McGinnis -- President

  David H Sherman -- Founder

  Yingqing Mao

  Kevin A Reynolds

  Paul Sheldon

  Yongquan (“alex”) Xue -- Chief Scientific Officer

Company News

There are no news available.